Protocol Ledger

NCT05143840 · Phase II · ACTIVE NOT RECRUITING

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Interventional Phase II clinical trial protocol NCT05143840 sponsored by University of Alabama at Birmingham in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-22 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05143840
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05143840
Protocol FieldVerified Registry Value
NCT IdentifierNCT05143840
Consolidated Lead SponsorUniversity of Alabama at Birmingham
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2022-04-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI